QuickNews

Analysts expected losses of $0.05 EPS. Earnings were driven primarily by sales of enzyme replacement therapy Naglazyme. The company communicated confidence that any regulatory concerns have been ironed out and this third FDA result will be positive.
Sources:

www.247wallst.com
www.onlinetradersforum.com
stock-promoter.thesubway.com
rosesryellow.blogspot.com
www.boardcentral.com
dandelionseedco.blogspot.com